Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Nominated Adviser Status

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
4.45    0.02 (0.45%)
Bid:
4.33
Ask:
4.52
Spread: 0.19 (4.388%)
Market Cap: £27.76m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Nominated Adviser Status

1 Nov 2018 13:38

RNS Number : 0704G
Immupharma PLC
01 November 2018
 

 

1 November 2018

 

 

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Nominated Adviser Status

 

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.

 

In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled.

 

The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.co.uk)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations 

+ 44 (0) 7721 413496

 

Northland Capital Partners Limited (NOMAD & Joint Broker)David Hignell, Dugald Carlean, Jamie Spotswood, Corporate FinanceRob Rees, Corporate Broking

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge

Chris Coleman

 

SI Capital (Joint Broker)

Nick Emerson

 

+44 (0)20 3861 6625

 

 

 

 

+44 (0) 20 3815 8880

 

 

+44 (0) 1483 413500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCUGGQWGUPRGWG
12345678910
Date   Source Headline
4th Jun 20267:10 amRNS-RIncanthera plc – Corporate Update & Board Changes
2nd Jun 20267:00 amRNSNotice of AGM & Annual Report & Accounts
27th May 20267:00 amRNSFinal Results
5th May 20267:00 amRNSIMM initiatesIND-Enabling Program for Kapiglucagon
10th Apr 20267:00 amRNSHolding(s) in Company
9th Apr 20267:00 amRNS-RChairman’s Open Letter to Shareholders
7th Apr 202611:45 amRNSResult of General Meeting and TVR
27th Mar 20267:00 amRNSP140 Program Update
23rd Mar 20267:00 amRNSResult of WRAP Retail Offer and TVR
19th Mar 20269:00 amRNSPublication of Circular
18th Mar 20267:00 amRNS-R‘Investor Meet Company’ presentation on 20 March
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £1.5 million
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
17th Mar 20267:00 amRNSP140 Update; Fundraise, Related Party Transaction
6th Jan 20264:11 pmRNSHolding(s) in Company
6th Jan 20267:00 amRNS-RAttending JPMorgan Conference & Biotech Showcase
24th Nov 20257:00 amRNSCorporate Update
4th Nov 20257:00 amRNSHolding(s) in Company
27th Oct 20257:00 amRNS-RIMMUPHARMA ATTENDING BIO-EUROPE
23rd Oct 20257:00 amRNSLaunch of Website; Corporate Update
13th Oct 20257:00 amRNSAppointment of Independent Non-Executive Director
6th Oct 20253:22 pmRNSHolding(s) in Company
17th Sep 20257:00 amRNSExercise of Warrants
11th Sep 20257:00 amRNSExercise of Warrants
1st Sep 20252:12 pmRNSAppointments of CSO and Head of R&D
1st Sep 20251:20 pmRNSImmuPharma Files New Patent Application for P140:
20th Aug 20251:36 pmRNSHolding(s) in Company
6th Aug 20257:00 amRNSInterim Results
12th Jun 202512:51 pmRNSResult of AGM
27th May 20253:13 pmRNSHolding(s) in Company
20th May 20257:00 amRNSNotice of AGM
19th May 20257:00 amRNSFinal Results
1st Apr 20257:00 amRNSWarrant Extension, Debt Conversion & Equity Issue
1st Apr 20257:00 amRNSExtension of Warrants in Incanthera to 30 Sep 2025
14th Mar 20257:00 amRNS-RIMM attending Bio-Europe Spring 17-19 March,Milan
13th Mar 20257:00 amRNSImmuPharma proves unique Mechanism of Action-P140
21st Feb 202511:36 amRNSHolding(s) in Company
13th Feb 20257:00 amRNS£2.91m fundraising; related party transactions
28th Jan 202512:57 pmRNSResponse to Share Price Movement
9th Jan 20257:00 amRNSBreakthrough Findings into Autoimmune Diseases
23rd Dec 20247:00 amRNSChange of Auditor
10th Dec 20242:36 pmRNSHolding(s) in Company
4th Dec 20247:00 amRNSAppointment of Company Secretary
9th Sep 20247:01 amRNSExtension of Warrants in Incanthera to 31 Mar 2025
9th Sep 20247:00 amRNSHalf-year Report
6th Aug 20241:41 pmRNSHolding(s) in Company
28th Jun 202412:17 pmRNSResult of AGM
6th Jun 20244:20 pmRNSHolding(s) in Company
5th Jun 20242:01 pmRNSNotice of AGM & Annual Report & Accounts
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
FUTR
Future
LSE
6.94%
EQN
EQN.L
LSE
0.00%
AGT
AVI Global Trust
LSE
-0.76%
XKS2
Xkorea
LSE
-4.86%
INPP
International Public Partnerships
LSE
0.00%
Trending
AVCT
Avacta Group
LSE
2.86%
ALRT
Defence Holdings
LSE
21.43%
PREM
Premier African Minerals
LSE
9.52%
ITM
Itm Power
LSE
-4.88%
FORG
Forgent
LSE
20.00%